Get the Stockscreener App
3.15
2.17%
-0.07
Ac Immune Sa stock is traded at $3.15, with a volume of 2.54M.
It is down -2.17% in the last 24 hours and down -3.96% over the past month.
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
See More
Previous Close:
$3.22
Open:
$3.43
24h Volume:
2.54M
Relative Volume:
4.03
Market Cap:
$316.89M
Revenue:
-
Net Income/Loss:
$-60.14M
P/E Ratio:
-4.4397
EPS:
-0.7095
Net Cash Flow:
$-68.17M
1W Performance:
+12.50%
1M Performance:
-3.96%
6M Performance:
+52.17%
1Y Performance:
+5.35%
1-Day Range:
$3.12
$3.80
1-Week Range:
$2.54
$3.80
52-Week Range:
$1.4299
$4.00
Ac Immune Sa Stock (ACIU) Company Profile
Compare ACIU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
3.15 | 323.93M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-31-24 | Initiated | BTIG Research | Buy |
| Feb-01-19 | Downgrade | UBS | Buy → Neutral |
| Jan-04-19 | Initiated | UBS | Buy |
| Apr-05-18 | Initiated | H.C. Wainwright | Buy |
| Mar-23-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Oct-18-16 | Initiated | Credit Suisse | Outperform |
| Oct-18-16 | Initiated | Jefferies | Buy |
| Oct-18-16 | Initiated | Leerink Partners | Outperform |
View All
Ac Immune Sa Stock (ACIU) Latest News
AC Immune SA (ACIU) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Aug Macro: Will AC Immune SA IMR stock outperform value peers2025 Technical Overview & Precise Swing Trade Alerts - moha.gov.vn
AC Immune Perks Up On Positive Parkinson’s Data - Citeline News & Insights
AC Immune’s Parkinson’s vaccine advances on promising biomarker profile - BioCentury
AC Immune Simulates Curiosity in Neurodegenerative Fight with Global Conference Plans - StocksToTrade
AC Immune (ACIU) Stock: Surges as ACI-7104.056 Shows Potential in Early Parkinson’s Disease - parameter.io
AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's - Benzinga
Promising Advancements in Parkinson’s Treatment: AC Immune’s ACI-7104 Vaccine Shows Groundbreaking Results - TipRanks
AC Immune SA: Navigating Market Momentum - timothysykes.com
ACIU Surges 30% on Positive Parkinson's Therapy Trial Results - GuruFocus
AC Immune’s Parkinson’s disease candidate shows positive Phase 2 results - TipRanks
ACIU: ACI-7104.056 shows promise in slowing Parkinson's progression with strong safety and efficacy - TradingView
AC Immune’s Parkinson’s treatment shows promise in slowing disease - Investing.com
AC Immune surges on Parkinson’s drug data (ACIU:NASDAQ) - Seeking Alpha
AC Immune (ACIU) Reports Encouraging Phase 2 Results for Parkins - GuruFocus
Why Is AC Immune Stock Up Over 23% Today? - Stocktwits
Ac Immune shares climb 32.6% premarket after co reports positive trial data for Parkinson's disease therapy - marketscreener.com
AC Immune stock rises after positive Parkinson’s disease trial data By Investing.com - Investing.com India
AC Immune Reports Promising Phase 2 Results for Parkinson’s Therapy - TipRanks
AC Immune Reports Positive Interim Phase 2 Data for ACI-7104.056 Indicating Potential to Slow Parkinson's Disease Progression - Quiver Quantitative
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease - GlobeNewswire Inc.
AC Immune SA's (NASDAQ:ACIU) stock price dropped 11% last week; retail investors would not be happy - simplywall.st
Sentiment Watch: Will AC Immune SA stock deliver long term returns - moha.gov.vn
Aug Reactions: Why ETFs are accumulating AC Immune SA IMR stockEarnings Risk Summary & Daily Stock Trend Watchlist - BỘ NỘI VỤ
Quarterly Risk: Why analysts upgrade AC Immune SA stock2025 Sector Review & Fast Momentum Stock Entry Tips - BỘ NỘI VỤ
How AC Immune SA (IMR) stock reacts to weak economyVolume Spike & Weekly High Potential Alerts - Newser
Is AC Immune SA (IMR) stock a top dividend aristocrat candidate2025 Short Interest & Reliable Price Action Trade Plans - Newser
How big funds are accumulating AC Immune SA (IMR) stock2025 Market Sentiment & Free Reliable Trade Execution Plans - Newser
Will AC Immune SA (IMR) stock profit from AI boomCPI Data & Comprehensive Market Scan Insights - Newser
Why AC Immune SA (IMR) stock trades below fair valueQuarterly Market Review & Capital Efficiency Focused Strategies - Newser
How geopolitical risks impact AC Immune SA (IMR) stock2025 Volume Leaders & Fast Entry Momentum Alerts - Newser
Will AC Immune SA (IMR) stock benefit from commodity supercycleWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
What analysts say about AC Immune SA IMR stockShort Selling Opportunities & Free Explosive Wealth Accumulation - earlytimes.in
Adversity is less terrifying than hope: AC Immune SA (ACIU) - Setenews
Is AC Immune SA stock a top pick in earnings seasonQuarterly Trade Report & Expert Approved Momentum Ideas - newser.com
Why millennials buy AC Immune SA (IMR) stockJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - newser.com
Will AC Immune SA stock recover faster than peersJuly 2025 Macro Moves & Community Supported Trade Ideas - newser.com
Is AC Immune SA (IMR) stock positioned for digital growth eraJuly 2025 Short Interest & AI Powered Buy/Sell Recommendations - newser.com
Why analysts remain bullish on AC Immune SA stockGDP Growth & Pattern Based Trade Signal System - newser.com
Can AC Immune SA stock resist sector downturnsEarnings Risk Summary & Expert Curated Trade Setup Alerts - newser.com
Signal strength of AC Immune SA stock in tech scannersBuy Signal & Momentum Based Trading Signals - newser.com
Why AC Immune SA stock remains on watchlistsWeekly Trade Recap & Free Community Consensus Stock Picks - newser.com
Ac Immune Sa Stock (ACIU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):